Instrument Inactif

Autres langues TearLab Corp Nasdaq

Actions

US8781932004

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TearLab Corporation Announces Board Appointments	09/12/21
TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	09/12/21
Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	09/11/21
MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	16/09/21
TearLab Appoints Adam Szaronos as Chief Commercial Officer	28/07/20
TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	09/07/20
Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	09/07/20
TearLab Corporation to Seek Acquisitions	09/07/20
TearLab: 1Q Earnings Snapshot	26/06/20
TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	26/06/20
Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	26/06/20
TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	08/06/20
TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	29/05/20
TEARLAB CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	13/05/20
TEARLAB CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	12/05/20
TEARLAB CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	11/05/20
TEARLAB CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Other Events, Financial Statements and Exhibits (form 8-K)	11/05/20
TearLab Corporation Announces Board Appointments	11/05/20
Tearlab Mulls Inorganic Growth Opportunities	11/05/20
TearLab : Announces Acquisition By Accelmed Partners And Related $25 Million Investment	11/05/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TearLab Corp Nasdaq

Actions

US8781932004

Autres langues

Filtres